BUCHANG PHARMA(SH:603858)2024-07-09 09:54Financial Performance Forecast - The company expects a net profit attributable to shareholders of approximately 186 million to 268 million yuan for the first half of 2024, representing a decrease of 478 million to 560 million yuan compared to the same period last year, a decline of 64.08% to 75.07%[2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is approximately 178 million to 260 million yuan, a decrease of 349 million to 431 million yuan year-on-year, reflecting a decline of 57.31% to 70.77%[2] - The total profit for the same period last year was 864 million yuan, with a net profit attributable to shareholders of 746 million yuan[4] Reasons for Profit Decline - The decrease in profit is primarily due to reduced sales from certain products due to medical insurance restrictions and inclusion in monitoring directories, leading to a decline in revenue[5] - The cost of main business increased year-on-year due to rising prices of traditional Chinese medicine materials, contributing to the profit decline[5] - The company experienced a weakened scale effect due to decreased revenue, resulting in increased cost rates for some products[5] - Government subsidies received in the current period were lower compared to the same period last year, impacting overall profitability[5] Audit and Data Reliability - The company has communicated the performance forecast with its annual audit accounting firm, confirming no significant uncertainties affecting the accuracy of the forecast[6] - The data provided is preliminary and subject to change, with the final financial figures to be disclosed in the official 2024 semi-annual report[6] - Investors are advised to pay attention to investment risks based on the preliminary nature of the forecast data[6]